N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists
Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphth...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 1997-08, Vol.40 (17), p.2674-2687 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2687 |
---|---|
container_issue | 17 |
container_start_page | 2674 |
container_title | Journal of medicinal chemistry |
container_volume | 40 |
creator | Elworthy, Todd R Ford, Anthony P. D. W Bantle, Gary W Morgans, David J Ozer, Rachel S Palmer, Wylie S Repke, David B Romero, Magarita Sandoval, Leticia Sjogren, Eric B Talamás, Francisco X Vazquez, Alfredo Wu, Helen Arredondo, Nicolas F Blue, David R DeSousa, Andrea Gross, Lisa M Kava, M. Shannon Lesnick, John D Vimont, Rachel L Williams, Timothy J Zhu, Quan-Ming Pfister, Jürg R Clarke, David E |
description | Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a “negative screen” for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure−affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA 2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2−3 orders of magnitude selectivity over the α1D-AR. |
doi_str_mv | 10.1021/jm970166j |
format | Article |
fullrecord | <record><control><sourceid>acs_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_2782102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>c664341131</sourcerecordid><originalsourceid>FETCH-LOGICAL-a167t-299a98318c95cc7202ec42fbc6ac45c04b64c4295b49ba2b748ff0d88fd8fa483</originalsourceid><addsrcrecordid>eNo9UUFOwzAQtBBIlMKBH-QAR4PtOIlzjAptkaoCoj1bG8dBDmkc2WlF4cIz-AYf4RG8hFRFnFaanRnt7CB0TskVJYxeV6s0ITSOqwM0oBEjmAvCD9GAEMYwi1l4jE68rwghIWXhAL3Pcea2dWta7eDNNNsaz38-PnHrbLutYWUaG9xoZzbQmY32gS2Dqe60s9Crgmxlih4EH4zXjeqMbaAOls56XWu1EwTfXxRnhdONVbrtrAuypoNn2xjf-VN0VELt9dnfHKLl-HYxmuLZ_eRulM0w0DjpMEtTSEVIhUojpRJGmFaclbmKQfFIEZ7HvAfSKOdpDixPuChLUghRFqIELsIhutj7tuAV1KWDRhkvW2dWfQrJEsH63_U0vKf1t-nX_zW4FxknYRLJxcOTnIxF_DhNF3Jne7nng_KysmvXh_eSErkrQv4XEf4CCAB-YQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists</title><source>American Chemical Society Journals</source><creator>Elworthy, Todd R ; Ford, Anthony P. D. W ; Bantle, Gary W ; Morgans, David J ; Ozer, Rachel S ; Palmer, Wylie S ; Repke, David B ; Romero, Magarita ; Sandoval, Leticia ; Sjogren, Eric B ; Talamás, Francisco X ; Vazquez, Alfredo ; Wu, Helen ; Arredondo, Nicolas F ; Blue, David R ; DeSousa, Andrea ; Gross, Lisa M ; Kava, M. Shannon ; Lesnick, John D ; Vimont, Rachel L ; Williams, Timothy J ; Zhu, Quan-Ming ; Pfister, Jürg R ; Clarke, David E</creator><creatorcontrib>Elworthy, Todd R ; Ford, Anthony P. D. W ; Bantle, Gary W ; Morgans, David J ; Ozer, Rachel S ; Palmer, Wylie S ; Repke, David B ; Romero, Magarita ; Sandoval, Leticia ; Sjogren, Eric B ; Talamás, Francisco X ; Vazquez, Alfredo ; Wu, Helen ; Arredondo, Nicolas F ; Blue, David R ; DeSousa, Andrea ; Gross, Lisa M ; Kava, M. Shannon ; Lesnick, John D ; Vimont, Rachel L ; Williams, Timothy J ; Zhu, Quan-Ming ; Pfister, Jürg R ; Clarke, David E</creatorcontrib><description>Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a “negative screen” for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure−affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA 2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2−3 orders of magnitude selectivity over the α1D-AR.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm970166j</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Biological and medical sciences ; Medical sciences ; Pharmacology. Drug treatments ; Urinary system</subject><ispartof>Journal of medicinal chemistry, 1997-08, Vol.40 (17), p.2674-2687</ispartof><rights>Copyright © 1997 American Chemical Society</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm970166j$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm970166j$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2782102$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Elworthy, Todd R</creatorcontrib><creatorcontrib>Ford, Anthony P. D. W</creatorcontrib><creatorcontrib>Bantle, Gary W</creatorcontrib><creatorcontrib>Morgans, David J</creatorcontrib><creatorcontrib>Ozer, Rachel S</creatorcontrib><creatorcontrib>Palmer, Wylie S</creatorcontrib><creatorcontrib>Repke, David B</creatorcontrib><creatorcontrib>Romero, Magarita</creatorcontrib><creatorcontrib>Sandoval, Leticia</creatorcontrib><creatorcontrib>Sjogren, Eric B</creatorcontrib><creatorcontrib>Talamás, Francisco X</creatorcontrib><creatorcontrib>Vazquez, Alfredo</creatorcontrib><creatorcontrib>Wu, Helen</creatorcontrib><creatorcontrib>Arredondo, Nicolas F</creatorcontrib><creatorcontrib>Blue, David R</creatorcontrib><creatorcontrib>DeSousa, Andrea</creatorcontrib><creatorcontrib>Gross, Lisa M</creatorcontrib><creatorcontrib>Kava, M. Shannon</creatorcontrib><creatorcontrib>Lesnick, John D</creatorcontrib><creatorcontrib>Vimont, Rachel L</creatorcontrib><creatorcontrib>Williams, Timothy J</creatorcontrib><creatorcontrib>Zhu, Quan-Ming</creatorcontrib><creatorcontrib>Pfister, Jürg R</creatorcontrib><creatorcontrib>Clarke, David E</creatorcontrib><title>N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a “negative screen” for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure−affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA 2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2−3 orders of magnitude selectivity over the α1D-AR.</description><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Urinary system</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNo9UUFOwzAQtBBIlMKBH-QAR4PtOIlzjAptkaoCoj1bG8dBDmkc2WlF4cIz-AYf4RG8hFRFnFaanRnt7CB0TskVJYxeV6s0ITSOqwM0oBEjmAvCD9GAEMYwi1l4jE68rwghIWXhAL3Pcea2dWta7eDNNNsaz38-PnHrbLutYWUaG9xoZzbQmY32gS2Dqe60s9Crgmxlih4EH4zXjeqMbaAOls56XWu1EwTfXxRnhdONVbrtrAuypoNn2xjf-VN0VELt9dnfHKLl-HYxmuLZ_eRulM0w0DjpMEtTSEVIhUojpRJGmFaclbmKQfFIEZ7HvAfSKOdpDixPuChLUghRFqIELsIhutj7tuAV1KWDRhkvW2dWfQrJEsH63_U0vKf1t-nX_zW4FxknYRLJxcOTnIxF_DhNF3Jne7nng_KysmvXh_eSErkrQv4XEf4CCAB-YQ</recordid><startdate>19970815</startdate><enddate>19970815</enddate><creator>Elworthy, Todd R</creator><creator>Ford, Anthony P. D. W</creator><creator>Bantle, Gary W</creator><creator>Morgans, David J</creator><creator>Ozer, Rachel S</creator><creator>Palmer, Wylie S</creator><creator>Repke, David B</creator><creator>Romero, Magarita</creator><creator>Sandoval, Leticia</creator><creator>Sjogren, Eric B</creator><creator>Talamás, Francisco X</creator><creator>Vazquez, Alfredo</creator><creator>Wu, Helen</creator><creator>Arredondo, Nicolas F</creator><creator>Blue, David R</creator><creator>DeSousa, Andrea</creator><creator>Gross, Lisa M</creator><creator>Kava, M. Shannon</creator><creator>Lesnick, John D</creator><creator>Vimont, Rachel L</creator><creator>Williams, Timothy J</creator><creator>Zhu, Quan-Ming</creator><creator>Pfister, Jürg R</creator><creator>Clarke, David E</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope></search><sort><creationdate>19970815</creationdate><title>N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists</title><author>Elworthy, Todd R ; Ford, Anthony P. D. W ; Bantle, Gary W ; Morgans, David J ; Ozer, Rachel S ; Palmer, Wylie S ; Repke, David B ; Romero, Magarita ; Sandoval, Leticia ; Sjogren, Eric B ; Talamás, Francisco X ; Vazquez, Alfredo ; Wu, Helen ; Arredondo, Nicolas F ; Blue, David R ; DeSousa, Andrea ; Gross, Lisa M ; Kava, M. Shannon ; Lesnick, John D ; Vimont, Rachel L ; Williams, Timothy J ; Zhu, Quan-Ming ; Pfister, Jürg R ; Clarke, David E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a167t-299a98318c95cc7202ec42fbc6ac45c04b64c4295b49ba2b748ff0d88fd8fa483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elworthy, Todd R</creatorcontrib><creatorcontrib>Ford, Anthony P. D. W</creatorcontrib><creatorcontrib>Bantle, Gary W</creatorcontrib><creatorcontrib>Morgans, David J</creatorcontrib><creatorcontrib>Ozer, Rachel S</creatorcontrib><creatorcontrib>Palmer, Wylie S</creatorcontrib><creatorcontrib>Repke, David B</creatorcontrib><creatorcontrib>Romero, Magarita</creatorcontrib><creatorcontrib>Sandoval, Leticia</creatorcontrib><creatorcontrib>Sjogren, Eric B</creatorcontrib><creatorcontrib>Talamás, Francisco X</creatorcontrib><creatorcontrib>Vazquez, Alfredo</creatorcontrib><creatorcontrib>Wu, Helen</creatorcontrib><creatorcontrib>Arredondo, Nicolas F</creatorcontrib><creatorcontrib>Blue, David R</creatorcontrib><creatorcontrib>DeSousa, Andrea</creatorcontrib><creatorcontrib>Gross, Lisa M</creatorcontrib><creatorcontrib>Kava, M. Shannon</creatorcontrib><creatorcontrib>Lesnick, John D</creatorcontrib><creatorcontrib>Vimont, Rachel L</creatorcontrib><creatorcontrib>Williams, Timothy J</creatorcontrib><creatorcontrib>Zhu, Quan-Ming</creatorcontrib><creatorcontrib>Pfister, Jürg R</creatorcontrib><creatorcontrib>Clarke, David E</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elworthy, Todd R</au><au>Ford, Anthony P. D. W</au><au>Bantle, Gary W</au><au>Morgans, David J</au><au>Ozer, Rachel S</au><au>Palmer, Wylie S</au><au>Repke, David B</au><au>Romero, Magarita</au><au>Sandoval, Leticia</au><au>Sjogren, Eric B</au><au>Talamás, Francisco X</au><au>Vazquez, Alfredo</au><au>Wu, Helen</au><au>Arredondo, Nicolas F</au><au>Blue, David R</au><au>DeSousa, Andrea</au><au>Gross, Lisa M</au><au>Kava, M. Shannon</au><au>Lesnick, John D</au><au>Vimont, Rachel L</au><au>Williams, Timothy J</au><au>Zhu, Quan-Ming</au><au>Pfister, Jürg R</au><au>Clarke, David E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1997-08-15</date><risdate>1997</risdate><volume>40</volume><issue>17</issue><spage>2674</spage><epage>2687</epage><pages>2674-2687</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a “negative screen” for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure−affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA 2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2−3 orders of magnitude selectivity over the α1D-AR.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><doi>10.1021/jm970166j</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1997-08, Vol.40 (17), p.2674-2687 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_pascalfrancis_primary_2782102 |
source | American Chemical Society Journals |
subjects | Biological and medical sciences Medical sciences Pharmacology. Drug treatments Urinary system |
title | N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T02%3A06%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=N-Arylpiperazinyl-N%E2%80%98-propylamino%20Derivatives%20of%20Heteroaryl%20Amides%20as%20Functional%20Uroselective%20%CE%B11-Adrenoceptor%20Antagonists&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Elworthy,%20Todd%20R&rft.date=1997-08-15&rft.volume=40&rft.issue=17&rft.spage=2674&rft.epage=2687&rft.pages=2674-2687&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm970166j&rft_dat=%3Cacs_pasca%3Ec664341131%3C/acs_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |